Long-term follow-up of basal cell carcinomas treated with perilesional interferon alfa 2b as monotherapy

Tucker, Stephen B.; Polasek, Jerry W.; Perri, Anthony J.; Goldsmith, Elizabeth A.

doi:10.1016/j.jaad.2006.02.035

Cited by 45 publications

(30 citation statements)

References 13 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One study reported follow-up after 15 years for 98 BCCs treated with interferon alfa-2b. 49 The 5-year success rate was 98%, with only two (2%) recurrences. The recurrences occurred at the sites of BCC on the nose and face (other than the nose).…”

Section: Discussionmentioning

confidence: 87%

“…Fifteen articles discuss the use of interferon alfa2b for the treatment of 542 BCCs. 35,[37][38][39][40][41][42][43][44][45][46][47][48][49][50] Of these, 65 were treated in a study using a sustained-release formulation of interferon alfa-2b and will be considered separately. 37 The remaining 477 tumors were located on the head and neck in 298 (62%) of the cases, on the trunk in 140 (30%), and on the extremities in 38 (8%).…”

Section: Bcc and Interferon Alfamentioning

confidence: 99%

See 1 more Smart Citation

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Kirby¹,

Miller²

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 87%

Section: Bcc and Interferon Alfamentioning

confidence: 99%

Intralesional chemotherapy for nonmelanoma skin cancer: A practical review

Kirby¹,

Miller²

2010

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Tucker ve ark. 12 10 yıl süren bir takip süreci sonrasında %96 oranında kür bildirmişlerdir. Bizim ise, interferon alfa-2b ve imikimod kombinasyonu ile tedavi ettiğimiz infiltratif bazal hücreli karsinomlu bir hastayı sunduğumuz, daha önceden yayınlanmış bir raporumuz 13 bulunmaktadır.…”

Section: Discussionunclassified

Bazal Hücreli Karsinomda Tek Başına veya İntralezyonel İnterferon ile Birlikte İmikimod Kullanımı ile Klinik Başarı

Sarıcaoğlu¹,

Üner²,

Turan³

et al. 2013

TURKDERM

View full text Add to dashboard Cite

ÖzetBazal hücreli karsinom (BHK), insanlarda en sık görülen deri kanseri tipidir. BHK'ların tedavisinde cerrahi, halen altın standart olarak yerini korumaktadır. Buna rağmen, cerrahiye uygun olmayan ve kozmetik kaygıları olan bireylerde imikimod krem ve intralezyonel interferon (IFN) alfa2b gibi, daha az invaziv, cerrahi olmayan seçenekler de bulunmaktadır. Yalnız başına imikimod ya da imikimod ile kombine olarak interferon alfa-2b ile başarılı bir şekilde tedavi ettiğimiz değişik alt tiplerde 11 BHK vakasını sunduk. 2005-2010 yılları arasında polikliniğimizde histopatolojik olarak BHK oldukları kanıtlanmış, tek başına ya da IFN alfa-2b ile kombine olarak imikimod ile tedavi edilmiş çeşitli alt tiplerdeki hastalar bu rapora dahil edildi. Sunduğumuz 11 hastadan sadece 4 'ü (3 infiltratif, 1 solid tipler) topikal imikimoda ek olarak haftada 3 gün intralezyonel interferon alfa2b 3 milyon IU tedavisi de almıştı. Geri kalan 7 hasta sadece imikimod %5 krem kullanmıştı. Tüm hastalarda bu tedavi seçenekleri ile tam iyileşme sağlandığı görüldü. Bu olgulardaki gözlemlerimiz, İmikimodun sadece yüzeyel değil; infiltratif, solid, nodüler tip BHK'larda da etkili olduğunu düşündürmektedir. İmikimod, sadece yüzeyel değil, aynı zamanda, infiltratif, solid ve nodüler tip BHK'larda da etkili olduğunu düşündürmektedir.İntralezyonel interferon alfa-2b'nin de BHK'larda etkili olduğu ve imikimod ile kombine edildiğinde sinerjistik etki gösterdiği bilinmektedir. Sum maryBasal cell carcinoma (BCC) is the most common type of skin cancer in humans. Surgery is still the gold standard for treating BCCs. However, there are also less-invasive, nonsurgical therapies such as imiquimod cream and intralesional interferon (IFN) alpha-2b for patients who are poor surgical candidates and who care about cosmetic outcomes. We report 11 patients with various subtypes of BCC successfully treated with either imiquimod alone or in combination with interferon alfa-2b. In this paper, we present 11 patients with various subtypes of histopathologically proven BCCs, who were treated with imiquimod or combination of imiquimod and IFN alpha-2b, in our outpatient clinic between 2005 and 2010. Of 11 patients, only 4 patients (3 infiltrative, 1 solid types) had received intralesional interferon alpha-2b at a dose of 3 million IU, 3 times a week combined with topical imiquimod while 7 patients had received only 5% imiquimod cream. All patients were cured with these regimens. Imiquimod is found to be effective not only in superficial, but also in infiltrative, solid, and nodular types. Intralesional interferon alpha-2b is also known to be effective in BCCs and it has a synergistic effect when combined with imiquimod. (Turkderm 2013; 47: 239-42)

show abstract

“…Table I summarizes these studies. [11][12][13][14][15][16][17] A new combination treatment modality of 5% topical imiquimod and intralesional interferon-a-2b was recently administered in a patient with an infiltrating BCC on the nasal ala and its success warrants enthusiasm for further investigation. Having refused excision, a regimen was started of topical imiquimod applied once daily for 5 consecutive days per week with a continual 6-week duration and interferona-2b (3 3 10 6 ) injected into the lesion 3 times per week for 2 weeks.…”

Section: Interferonmentioning

confidence: 99%